Cargando…

Quality of life after intratympanic steroid injection for Ménière's disease

OBJECTIVE: This study explores how treatment with intratympanic steroid injection affects quality of life, as well as several subjective complaints in patients with Ménière's disease. METHODS: Patients filled in the Ménière's Disease Outcome Questionnaire (MDOQ) and answered questions abou...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenck, Annejet A., Bommeljé, Claire C., van Benthem, Peter Paul G., Blom, Henk M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194969/
https://www.ncbi.nlm.nih.gov/pubmed/35734074
http://dx.doi.org/10.1002/lio2.798
_version_ 1784726862059012096
author Schenck, Annejet A.
Bommeljé, Claire C.
van Benthem, Peter Paul G.
Blom, Henk M.
author_facet Schenck, Annejet A.
Bommeljé, Claire C.
van Benthem, Peter Paul G.
Blom, Henk M.
author_sort Schenck, Annejet A.
collection PubMed
description OBJECTIVE: This study explores how treatment with intratympanic steroid injection affects quality of life, as well as several subjective complaints in patients with Ménière's disease. METHODS: Patients filled in the Ménière's Disease Outcome Questionnaire (MDOQ) and answered questions about subjective complaints. Scores before and after treatment were compared using paired t tests. RESULTS: Forty‐nine patients treated with intratympanic steroid injection were included. Quality of life was improved in 36 (73%) patients, the same in 9 (18%) patients, and lower in 4 (8%) patients. Overall, the mean change in MDOQ was +20.6 points (95% confidence interval +14.5 to +26.7 points, p < 0.001). The improvement was seen in the emotional, physical, and mental domain. Most patients experienced less vertigo and instability but did not notice change in subjective hearing, tinnitus, or aural fullness after treatment. CONCLUSION: Treatment with intratympanic steroid injection leads to an improvement in quality of life in most patients. Moreover, the procedure is only minimally invasive. Based on the findings in this study, treatment with ITS should be discussed with every patient suffering from vertigo attacks due to active Ménière's disease. LEVEL OF EVIDENCE: Level 4
format Online
Article
Text
id pubmed-9194969
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-91949692022-06-21 Quality of life after intratympanic steroid injection for Ménière's disease Schenck, Annejet A. Bommeljé, Claire C. van Benthem, Peter Paul G. Blom, Henk M. Laryngoscope Investig Otolaryngol Otology, Neurotology, and Neuroscience OBJECTIVE: This study explores how treatment with intratympanic steroid injection affects quality of life, as well as several subjective complaints in patients with Ménière's disease. METHODS: Patients filled in the Ménière's Disease Outcome Questionnaire (MDOQ) and answered questions about subjective complaints. Scores before and after treatment were compared using paired t tests. RESULTS: Forty‐nine patients treated with intratympanic steroid injection were included. Quality of life was improved in 36 (73%) patients, the same in 9 (18%) patients, and lower in 4 (8%) patients. Overall, the mean change in MDOQ was +20.6 points (95% confidence interval +14.5 to +26.7 points, p < 0.001). The improvement was seen in the emotional, physical, and mental domain. Most patients experienced less vertigo and instability but did not notice change in subjective hearing, tinnitus, or aural fullness after treatment. CONCLUSION: Treatment with intratympanic steroid injection leads to an improvement in quality of life in most patients. Moreover, the procedure is only minimally invasive. Based on the findings in this study, treatment with ITS should be discussed with every patient suffering from vertigo attacks due to active Ménière's disease. LEVEL OF EVIDENCE: Level 4 John Wiley & Sons, Inc. 2022-05-17 /pmc/articles/PMC9194969/ /pubmed/35734074 http://dx.doi.org/10.1002/lio2.798 Text en © 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Otology, Neurotology, and Neuroscience
Schenck, Annejet A.
Bommeljé, Claire C.
van Benthem, Peter Paul G.
Blom, Henk M.
Quality of life after intratympanic steroid injection for Ménière's disease
title Quality of life after intratympanic steroid injection for Ménière's disease
title_full Quality of life after intratympanic steroid injection for Ménière's disease
title_fullStr Quality of life after intratympanic steroid injection for Ménière's disease
title_full_unstemmed Quality of life after intratympanic steroid injection for Ménière's disease
title_short Quality of life after intratympanic steroid injection for Ménière's disease
title_sort quality of life after intratympanic steroid injection for ménière's disease
topic Otology, Neurotology, and Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194969/
https://www.ncbi.nlm.nih.gov/pubmed/35734074
http://dx.doi.org/10.1002/lio2.798
work_keys_str_mv AT schenckannejeta qualityoflifeafterintratympanicsteroidinjectionformenieresdisease
AT bommeljeclairec qualityoflifeafterintratympanicsteroidinjectionformenieresdisease
AT vanbenthempeterpaulg qualityoflifeafterintratympanicsteroidinjectionformenieresdisease
AT blomhenkm qualityoflifeafterintratympanicsteroidinjectionformenieresdisease